Noopept
| 제품명 | Noopept |
| 다른 이름 | GVS-111; N-Phenylacetyl-L-prolylglycine ethyl ester |
| CAS 번호 | 157115-85-0 |
| 분자식 | C₁₇H₂₂N₂O₄ |
| 분자량 | 334.37 g/mol |
| 외관 | 흰색에서 미백색의 결정성 분말 |
| 분석법 (HPLC) | ≥ 99.0% |
| 융점 | 95–98°C |
| 건조 손실 | ≤ 0.5% |
| 소각 잔류물 | ≤ 0.1% |
| 중금속 | 10 ppm 이하 |
도움이 필요하신가요? 저희 팀에 문의해 주세요
Noopept (developmental code GVS-111) is a dipeptide nootropic compound developed in Russia in the 1990s as a novel cognitive enhancer with neuroprotective properties. Structurally, it is a cycloprolyl-glycine derivative that shares some pharmacological similarities with racetams (particularly piracetam), but with significantly higher potency—estimated to be approximately 1,000 times more potent than piracetam.
Key : Unlike most nootropics that require weeks to show effects, Noopept has demonstrated rapid onset in research models. It exhibits both cognitive-enhancing 그리고 neuroprotective properties, including protection against oxidative stress, excitotoxicity, and ischemia-reperfusion injury. Noopept also increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus.
Noopept exerts its effects through multiple pathways, distinguishing it from classic racetams:
| 진로 | 메커니즘 | Research Finding |
|---|---|---|
| BDNF/NGF upregulation | Increases brain-derived neurotrophic factor and nerve growth factor in hippocampus | Supports synaptic plasticity, neurogenesis |
| AMPA/kainate receptor modulation | Positive allosteric modulation (similar to racetams) | Enhances glutamatergic transmission |
| 신경 보호 | Reduces oxidative stress, inhibits lipid peroxidation, protects against excitotoxicity | Preclinical models of ischemia, traumatic brain injury |
| Cholinergic system | May enhance acetylcholine release (indirect) | Memory and learning support |
| Anti-inflammatory | Reduces neuroinflammation (preclinical) | 신경 보호 |
Noopept has been shown to protect against neurodegeneration in animal models of Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. It reduces amyloid-β toxicity and may have disease-modifying potential (preclinical only).
LyvBio 주식회사. is a GMP-certified supplier of high-purity Noopept (GVS-111) for research and development applications.
공급 역량:
분석법 (HPLC): ≥99.0%
양식: 결정성 분말
월간 처리량: 20kg 이상
대량 주문: 1g – 10kg
리드 타임: 3-5 business days (stock items)
문서: COA, MSDS, HNMR , HPLC chromatogram, stability data
Quality assurance:
HPLC purity with UV detection
Residual solvents tested (meets USP <467>)
Heavy metals tested (ICP-MS)
Structural confirmation (NMR upon request)
📧 문의: info@lyvbio.com
| 매개변수 | 사양 | 시험 방법 |
|---|---|---|
| 분석법 (HPLC) | ≥ 99.0% | HPLC-UV (210 nm) |
| 외관 | 흰색에서 미백색의 결정성 분말 | 시각적 |
| 식별 | HPLC 유지 시간, NMR (요청 시) | HPLC / NMR |
| 융점 | 95–98°C | USP |
| 건조 손실 | ≤ 0.5% | USP |
| 소각 잔류물 | ≤ 0.1% | USP |
| 중금속 | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| 관련 물질 | 단일 불순물 ≤ 0.5%; 총 불순물 ≤ 1.0% | HPLC-UV |
| 잔류 용매 | USP 소개 | GC |
| 입자 크기 | 95% ~ 80 메쉬 | 체 분석 |
Q: Is Noopept the same as Piracetam?
A: No. Noopept is a dipeptide derivative with different chemical structure, significantly higher potency (~1,000x), and distinct mechanisms (including BDNF/NGF upregulation). It is not a racetam, though it shares some pharmacological similarities.
Q: Is Noopept FDA-approved?
A: 아니요. Noopept is not FDA-approved for medical use in the United States. It is available as a research chemical for laboratory use only. It has been used as a prescription medication in Russia.
Q: What is the difference between Noopept and other nootropics?
A: Noopept is unique in its ability to upregulate BDNF and NGF in the hippocampus—a property not shared by classic racetams. It is also significantly more potent (microgram vs. milligram dosing).
Q: What is the primary active metabolite of Noopept?
A: Cycloprolylglycine (CPG). Noopept is rapidly metabolized to CPG, which is believed to contribute significantly to its pharmacological effects.
Q: Does Noopept have neuroprotective properties?
A: Yes. Preclinical studies have demonstrated neuroprotective effects in models of stroke, traumatic brain injury, excitotoxicity, and neurodegeneration (Alzheimer’s, Parkinson’s models).
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing and neuroprotective effects at 0.1–1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Noopept?
A: Limited human studies have been conducted in Russia, where Noopept is approved as a prescription nootropic.
문의: info@lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese